Longitudinal Assessment of an 800 µg Dose of HEBERSaVax in Non-Human Primates over Six Months

Background/Objectives: HEBERSaVax is a therapeutic cancer vaccine based on recombinant human VEGF antigen adjuvated with VSSP or Aluminum Phosphate (AP). Clinical trials demonstrated the vaccine’s safety and tolerability, with predominantly mild to moderate (grade 1–2) local adverse events. Initial...

Descrición completa

Detalles Bibliográficos

Principais autores:	Camila Canaán-Haden, Isabel Gonzalez-Moya, Monica Bequet-Romero, Olivia Cabanillas-Bernal, Rafael Martínez-Castillo, Camilo Cerioli-Pentón, Nayelis Chavez-Castro, Marta Ayala-Ávila, Jorge Castro-Velazco, Alexei F. Licea-Navarro, Yanelys Morera-Díaz
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2026-02-01
Series:	Vaccines
Assuntos:	HEBERSaVax VEGF vaccine immunogenicity safety
Acceso en liña:	https://www.mdpi.com/2076-393X/14/3/230
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!